Reconsidering the usefulness of using long-acting injectable buprenorphine as a tapering tool: a case report of delayed withdrawal months after last dose - Scorecard - MDSpire
Advertisement
Reconsidering the usefulness of using long-acting injectable buprenorphine as a tapering tool: a case report of delayed withdrawal months after last dose
Clinical Scorecard: Evaluating the Efficacy of Long-Acting Injectable Buprenorphine for Tapering: A Case Study of Prolonged Withdrawal After Final Administration
At a Glance
Category
Detail
Condition
Opioid Use Disorder (OUD)
Key Mechanisms
Delayed withdrawal symptoms due to pharmacokinetics of long-acting injectable buprenorphine.
Target Population
Patients with OUD seeking discontinuation from buprenorphine therapy.
Care Setting
Clinical management of opioid tapering strategies.
Key Highlights
Delayed withdrawal symptoms can occur months after LAIB administration.
Loss of kappa opioid receptor antagonism may exacerbate mood-like symptoms.
Comprehensive tapering protocols and extended monitoring are essential.
Bridging strategies may be necessary during tapering.
Differential diagnosis should consider delayed withdrawal versus new psychiatric disorders.
Guideline-Based Recommendations
Diagnosis
Consider delayed buprenorphine withdrawal in patients with emerging symptoms post-taper.
Management
Utilize symptomatic agents or buprenorphine rescue as needed during tapering.
Monitoring & Follow-up
Extended monitoring for 6–12 months is recommended after LAIB administration.
Risks
Informed consent regarding delayed withdrawal risks should be obtained.
Patient & Prescribing Data
Individuals with a history of opioid use disorder in remission.
Single doses of LAIB may lead to prolonged withdrawal symptoms requiring careful management.
Clinical Best Practices
Implement shared decision-making when transitioning to LAIB.
Monitor pharmacokinetics of buprenorphine to inform clinical decisions.
Recognize and address atypical withdrawal symptoms that may mimic psychiatric disorders.
